Tumor therapeutic agent improved through IL-12/CD62L fusion protein and preparation method and application thereof

Abstract

The invention provides an efficient and low-toxin tumor therapeutic agent and a preparation method and application thereof, and particularly provides IL-12 / CD62L fusion protein. Anti-tumor T cells are modified through slow viruses containing IL-12 / CD62L fusion genes, and by means of specific cleavage and release induced by activation of CD62L tumor antigen dependence, release of cell membrane surface IL-12 activated through tumor antigens is achieved. A is shown through experiments, fixed-point and timed release of IL-12 can be achieved locally on tumors attacked by the T cells, so that the immune microenvironment of T cell-tumor tissue is changed, and accordingly the anti-tumor immune effect is the maximum. Besides, the toxic and side effects are remarkably reduced.

Description

technical field

[0001] The invention relates to the field of medicine, in particular to a tumor therapeutic agent transformed by IL-12 / CD62L fusion protein and its preparation method and application. The invention provides a kind of IL-12 / CD62L gene-modified T cells with enhanced anti-tumor effect. Background technique

[0002] IL-12 is a very important immune stimulating factor. IL-12 is a covalently linked heterodimeric cytokine composed of p35 and p40 subunits that is secreted by activated immune cells in vivo. IL-12 is an important regulatory factor of cellular immunity, and plays a role through NK cells and CTL in anti-infection immunity and immunity of malignant tumors.

[0003] Individuals who are congenitally deficient or nonresponsive to IL-12 have profoundly deficient immunity against infection. A series of preclinical experimental models have confirmed that the intervention of IL-12 can significantly prolong the survival of tumor-bearing animal models. [0004...

Images